retatrutide ly3437943 parkinson's disease clinical trial Meets Weight Loss Endpoints in Phase 3 Obesity Weight loss is often 0896245000581 Flavor:Chocolate + Vanilla

retatrutide ly3437943 parkinson's disease clinical trial Meets Weight Loss Endpoints in Phase 3 Obesity Weight loss is often 0896245000581 Flavor:Chocolate + Vanilla

Weight loss is often the goal for those taking GLP-1 medications. But in some cases, people shed more than just pounds. They also lose hair. Listen in as endocrinologist Kathy Zhou explains

The result is a look commonly referred to as “Ozempic Face,” marked by facial hollowing, sagging skin, and visible signs of aging

0896245000581

Flavor:Chocolate + Vanilla

If the end of compounded GLP-1 drugs means the costs go up, some number of consumers will doubtlessly stop taking them, which could shift some of the marketing from the During demographic to the After group